206 related articles for article (PubMed ID: 16792830)
1. Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen.
Li L; Zhou Y; Bell CJ; Earley MC; Hannon WH; Mei JV
J Med Screen; 2006; 13(2):79-84. PubMed ID: 16792830
[TBL] [Abstract][Full Text] [Related]
2. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
3. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
4. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
5. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
6. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
8. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
9. Screening for cystic fibrosis in dried blood spots of newborns.
Audrézet MP; Costes B; Ghanem N; Fanen P; Verlingue C; Morin JF; Mercier B; Goossens M; Férec C
Mol Cell Probes; 1993 Dec; 7(6):497-502. PubMed ID: 8145780
[TBL] [Abstract][Full Text] [Related]
10. Thirty-years of screening for cystic fibrosis in East Anglia.
Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
[TBL] [Abstract][Full Text] [Related]
11. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
12. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
13. Pilot study for cystic fibrosis neonatal screening: the Cuban experience.
Castells EM; Sánchez A; Frómeta A; Mokdse Y; Ozunas N; Licourt T; Arteaga AL; Silva E; Collazo T; Rodríguez F; Martín O; Espinosa M; Del Río L; Pérez PL; Morejón G; Almira C; Núñez Z; Melchor A; González EC
Clin Chem Lab Med; 2020 Oct; 58(11):1857-1864. PubMed ID: 32352395
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
[TBL] [Abstract][Full Text] [Related]
15. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
Hammond KB; Abman SH; Sokol RJ; Accurso FJ
N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland.
Barben J; Gallati S; Fingerhut R; Schoeni MH; Baumgartner MR; Torresani T;
J Cyst Fibros; 2012 Jul; 11(4):332-6. PubMed ID: 22300503
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening.
Therrell BL; Hannon WH; Hoffman G; Ojodu J; Farrell PM
Mol Genet Metab; 2012 May; 106(1):1-6. PubMed ID: 22425451
[TBL] [Abstract][Full Text] [Related]
20. Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis.
Mérelle ME; Scheffer H; De Jong D; Dankert-Roelse JE
Acta Paediatr; 2006 Nov; 95(11):1424-8. PubMed ID: 17062471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
